Swaleh Bahamadi, MD
Hematology & Oncology · Wilmington, NCNPI 1649320144
Payments from drug & device makers
Across 108 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$231
- Takeda Pharmaceuticals U.S.A., Inc.$168
- Daiichi Sankyo Inc.$149
- Merck$148
- Astellas Pharma US Inc$119
- Pfizer$116
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,09891%
- Education$2039%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 13 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $168 |
| Daiichi Sankyo Inc. | 6 | $149 |
| Merck | 6 | $148 |
| Astellas Pharma US Inc | 3 | $119 |
| Pfizer | 6 | $116 |
| Novartis | 6 | $116 |
| Johnson & Johnson | 6 | $114 |
| AbbVie | 5 | $102 |
| AstraZeneca(2 entities) | 5 | $99 |
| Seagen Inc. | 1 | $95 |
| Genentech USA, Inc. | 5 | $90 |
| Gilead | 5 | $84 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Exelixis Inc. | 2 | $45 |
| Beone Medicines USA, Inc. | 2 | $43 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Amgen | 2 | $42 |
| Tersera Therapeutics LLC | 2 | $39 |
| Array Biopharma Inc | 2 | $37 |
| EMD Serono, Inc. | 2 | $32 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Bayer | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Adaptive Biotechnologies Corporation | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
| Legend Biotech USA Inc. | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $15 |
How this compares
$2,301 in reported general payments places this provider in the 35th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $670,253 |
| IbrancePalbociclib | 37 | $554,806 |
| SprycelDasatinib | 31 | $447,444 |
| PomalystPomalidomide | 18 | $408,102 |
| PromactaEltrombopag Olamine | 11 | $380,161 |
| CalquenceAcalabrutinib Maleate | 26 | $361,198 |
| KisqaliRibociclib Succinate | 19 | $314,069 |
| InlytaAxitinib | 14 | $256,673 |
| Lenalidomide | 16 | $227,530 |
| NerlynxNeratinib Maleate | 11 | $210,694 |
| LonsurfTrifluridine/Tipiracil Hcl | 16 | $192,089 |
| XtandiEnzalutamide | 13 | $173,854 |
| VenclextaVenetoclax | 11 | $162,065 |
| ErleadaApalutamide | 11 | $155,054 |
| JakafiRuxolitinib Phosphate | 14 | $141,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis | $116 | $941,001229 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $19 | $855,54549 claims |
| NovartisPromacta, Kisqali, Gleevec | $116 | $803,86342 claims |
| Bristol Myers SquibbRevlimid | $231 | $670,25339 claims |
| AstraZenecaCalquence | $99 | $361,19826 claims |
| AbbVieVenclexta, Creon | $102 | $262,04342 claims |
| Johnson & JohnsonErleada, Xarelto | $114 | $202,55164 claims |
| Astellas Pharma US IncXtandi | $119 | $173,85413 claims |
| Incyte CorporationJakafi | $19 | $141,45914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Wilmington
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
- Autumn McReeChapel Hill$5.5M
- Darla LilesGreenville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.